Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents

被引：28

作者：

Rotger M. ^{[1
]}

Csajka C. ^{[1
]}

Telenti A. ^{[1
]}

机构：

[1] Institute of Microbiology, University Hospital, Lausanne

来源：

Current HIV/AIDS Reports | 2006年 / 3卷 / 3期

关键词：

Efavirenz; Nevirapine; Indinavir; Saquinavir; Atazanavir;

D O I：

10.1007/BF02696655

中图分类号：

学科分类号：

摘要：

Variable antiretroviral therapy (ART) drug response likely reflects the combined influence of environment, underlying disease, concurrent drugs, and genetics. Gender exerts modest or negligible effects on ART disposition, and it is expected to have limited clinical implication, although it should be accounted for in large population studies. Ethnic denominations have, with the notable exception of efavirenz, no clear influence on ART disposition. Exploration of genetic factors might offer a better comprehension to the largely unpredictable and unresolved variability in ART concentrations and related toxicity or treatment outcome. Despite the negative perception of genetic research among the general public, this type of investigation is now widely accepted by concerned parties: patients, relatives, and study volunteers. Copyright © 2006 by Current Science Inc.

引用

页码：118 / 125

页数：7

共 55 条

[1]

Gandhi M., Aweeka F., Greenblatt R.M., Blaschke T.F., Sex differences in pharmacokinetics and pharmacodynamics, Annu Rev Pharmacol Toxicol, 44, pp. 499-523, (2004)

[2]

Brendel K., Legrand M., Taburet A.M., Et al., Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy, Fundam Clin Pharmacol, 19, pp. 373-383, (2005)

[3]

Csajka C., Marzolini C., Fattinger K., Et al., Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus, Antimicrob Agents Chemother, 48, pp. 3226-3232, (2004)

[4]

Kappelhoff B.S., Huitema A.D., Sankatsing S.U., Et al., Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients, Br J Clin Pharmacol, 60, pp. 276-286, (2005)

[5]

Burger D.M., Siebers M.C., Hugen P.W.H., Et al., Pharmacokinetic variability caused by gender: Do women have higher indinavir exposure than in men?, J Acquir Immune Defic Syndr, 29, pp. 101-102, (2002)

[6]

Ribera E., Lopez R.M., Diaz M., Et al., Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults, Antimicrob Agents Chemother, 48, pp. 4256-4262, (2004)

[7]

Pai M.P., Schriever C.A., Az-Linares M., Et al., Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1, Pharmacotherapy, 24, pp. 592-599, (2004)

[8]

Fletcher C.V., Jiang H., Brundage R.C., Et al., Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359, J Infect Dis, 189, pp. 1176-1184, (2004)

[9]

Crommentuyn K.M., Kappelhoff B.S., Mulder J.W., Et al., Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients, Br J Clin Pharmacol, 60, pp. 378-389, (2005)

[10]

Jackson K.A., Rosenbaum S.E., Kerr B.M., Et al., A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial, Antimicrob Agents Chemother, 44, pp. 1832-1837, (2000)

← 1 2 3 4 5 6 →